hikma

Hikma acquires the rights to a portfolio of Takeda brands for the MENA region

• People and Community

Hikma acquires the rights to a portfolio of Takeda brands for the MENA region

AETOSWire December 20, 2024

Amman, Jordan Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today announces that it has agreed...

Read More Read more about Hikma acquires the rights to a portfolio of Takeda brands for the MENA region

Hikma continues strong strategic execution and reiterates guidance

• General

Hikma continues strong strategic execution and reiterates guidance

AETOSWire November 7, 2024

London, United Kingdom Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on...

Read More Read more about Hikma continues strong strategic execution and reiterates guidance

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

• People and Community

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

AETOSWire April 25, 2024

Amman, Jordan Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current...

Read More Read more about Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

Hikma delivers strong 2023 performance and a positive outlook for 2024

• People and Community

Hikma delivers strong 2023 performance and a positive outlook for 2024

AETOSWire February 22, 2024

Amman, Jordan Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results...

Read More Read more about Hikma delivers strong 2023 performance and a positive outlook for 2024

Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets

• Health and Family

Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets

AETOSWire February 12, 2024

into the Saudi, Jordanian and Iraqi Markets Amman, Jordan Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has...

Read More Read more about Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets

Activ Surgical, a Hikma Ventures portfolio company, completes the first international procedure using ActivSight™ Intelligent Light at Abdali Hospital in Jordan

• Health and Family

Activ Surgical, a Hikma Ventures portfolio company, completes the first international procedure using ActivSight™ Intelligent Light at Abdali Hospital in Jordan

AETOSWire January 22, 2024

Amman, Jordan Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that Activ Surgical, a digital...

Read More Read more about Activ Surgical, a Hikma Ventures portfolio company, completes the first international procedure using ActivSight™ Intelligent Light at Abdali Hospital in Jordan

Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology

• Health and Family

Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology

AETOSWire January 8, 2024

to the Middle East and North Africa Amman, Jordan Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today...

Read More Read more about Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology

Hikma continues strong momentum across the Group and upgrades guidance for 2023

• Main News

Hikma continues strong momentum across the Group and upgrades guidance for 2023

AETOSWire November 2, 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Read More Read more about Hikma continues strong momentum across the Group and upgrades guidance for 2023

Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

• Main News

Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

AETOSWire October 14, 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license...

Read More Read more about Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

Hikma and Cosmo partner on exclusive licensing agreement for Winlevi® (Clascoterone) for the Middle East and North Africa

• General

Hikma and Cosmo partner on exclusive licensing agreement for Winlevi® (Clascoterone) for the Middle East and North Africa

AETOSWire October 2, 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with...

Read More Read more about Hikma and Cosmo partner on exclusive licensing agreement for Winlevi® (Clascoterone) for the Middle East and North Africa